Pages that link to "Q31139684"
Jump to navigation
Jump to search
The following pages link to Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression (Q31139684):
Displaying 50 items.
- Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases (Q26859909) (← links)
- Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. (Q27005950) (← links)
- Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington's Disease (Q27022757) (← links)
- The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy (Q28473538) (← links)
- PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease (Q28547107) (← links)
- Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease (Q28748849) (← links)
- The HSP70 chaperone machinery: J proteins as drivers of functional specificity (Q29616140) (← links)
- Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease (Q30474580) (← links)
- Protective effect of geranylgeranylacetone via enhancement of HSPB8 induction in desmin-related cardiomyopathy (Q30862326) (← links)
- To fold or not to fold: modulation and consequences of Hsp90 inhibition (Q33531705) (← links)
- cAMP-response element-binding protein and heat-shock protein 70 additively suppress polyglutamine-mediated toxicity in Drosophila (Q33900572) (← links)
- Heat shock protein 70 (hsp70) as an emerging drug target. (Q33956906) (← links)
- Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease (Q34114458) (← links)
- Hsp70 and its molecular role in nervous system diseases (Q34170760) (← links)
- Targets for future clinical trials in Huntington's disease: what's in the pipeline? (Q34435001) (← links)
- Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism (Q34506269) (← links)
- The novel hydroxylamine derivative NG-094 suppresses polyglutamine protein toxicity in Caenorhabditis elegans (Q34998152) (← links)
- hsp72, a host determinant of measles virus neurovirulence (Q35139663) (← links)
- Genetic and environmental factors in the pathogenesis of Huntington's disease (Q35639868) (← links)
- Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis (Q35764321) (← links)
- Chaperone proteins and brain tumors: potential targets and possible therapeutics (Q35800492) (← links)
- Suppression of protein aggregation by chaperone modification of high molecular weight complexes (Q35888633) (← links)
- Modulation of neurodegeneration by molecular chaperones (Q35990274) (← links)
- Opinion: What is the role of protein aggregation in neurodegeneration? (Q36259086) (← links)
- The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies (Q36358871) (← links)
- Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. (Q36456362) (← links)
- Sex-dependent effect of BAG1 in ameliorating motor deficits of Huntington disease transgenic mice (Q36701847) (← links)
- Molecular chaperones as regulators of cell death (Q37310205) (← links)
- Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease (Q37336253) (← links)
- The heat shock factor family and adaptation to proteotoxic stress (Q37800068) (← links)
- Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseases (Q38093796) (← links)
- Barcoding heat shock proteins to human diseases: looking beyond the heat shock response (Q38203487) (← links)
- From pathways to targets: understanding the mechanisms behind polyglutamine disease. (Q38259591) (← links)
- The role of HSP70 and its co-chaperones in protein misfolding, aggregation and disease. (Q38285309) (← links)
- Molecular chaperones and neuronal proteostasis (Q38377410) (← links)
- Heat shock proteins as potential targets for protective strategies in neurodegeneration (Q38815318) (← links)
- Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders. (Q38818474) (← links)
- Dexamethasone induces heat shock response and slows down disease progression in mouse and fly models of Huntington's disease (Q39037984) (← links)
- Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models (Q40392026) (← links)
- Hsp70 and Hsp40 chaperones do not modulate retinal phenotype in SCA7 mice. (Q40502075) (← links)
- Proteostasis of Huntingtin in Health and Disease (Q41183326) (← links)
- The heat shock response in neurons and astroglia and its role in neurodegenerative diseases. (Q41716408) (← links)
- Adverse outcome pathways: opportunities, limitations and open questions (Q42307037) (← links)
- Elevation of the Hsp70 chaperone does not effect toxicity in mouse models of familial amyotrophic lateral sclerosis (Q44197126) (← links)
- CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. (Q45298680) (← links)
- Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation (Q45304513) (← links)
- Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease (Q45304607) (← links)
- Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice (Q46739909) (← links)
- Hsp70 suppresses apoptosis in sympathetic neurones by preventing the activation of c-Jun (Q50659448) (← links)
- Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease. (Q55295842) (← links)